Anti-androgen Articles

Articles

  • A new label-free screen for steroid 5α-reductase inhibitors using LC-MS.

    Steroid 5α-reductase (S5αR) plays an important role in metabolizing testosterone into active androgen dihydrotestosterone (DHT) which is involved in many androgen dependent disorders, such as androgenic alopecia, benign prostatic hyperplasia and acne.

    Published October 31, 2016
  • A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

    Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world.

    Published September 7, 2015
  • Androgen Receptor Signaling in Bladder Cancer.

    Emerging preclinical findings have indicated that steroid hormone receptor signaling plays an important role in bladder cancer outgrowth. In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer.

    Published March 9, 2017
  • Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

    Consumption of cruciferous vegetables is associated with a decreased risk of developing prostate cancer. Antineoplastic effects of cruciferous vegetables are attributable to bioactive indoles, most prominently, 3, 3'-diindolylmethane (DIM).

    Published April 22, 2016
  • Quality of Life-Focused Decision-Making for Prostate Cancer.

    Quality of life (QoL) outcomes have been reported in the literature and incorporated in decision-making in localized prostate cancer management for decades. Until recently, there was less emphasis on understanding the QoL effects of therapies for patients with advanced disease, possibly because there were fewer options for treatment.

    Published September 2, 2019
  • Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.

    Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in the United States and its progression is tightly associated with the androgen/androgen receptor (AR) signals. Men castrated before puberty (eunuchs) or men with inherited deficiency of type II 5α-reductase (with failure to convert testosterone to the more potent dihydrotestosterone) (DHT) do not develop PCa.

    Published March 30, 2017